4D Molecular Therapeutics

View All

Pharma News For Astellas, AnaMar, Biosyngen
4DMT Presents Data From Phase II PRISM Clinical Trial; Adaptimmune Announces FDA Acceptance of Biologics License Application for Afami-cel; Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA; AnaMar Announces US and EU Orphan Drug Designation for AM1476; Biosyngen Announces FDA Fast Track Designation for BST02; Acepodia Announces FDA Clearance of IND Application for ACE2016

4DMT Presents Positive Interim Data from Randomized Phase II PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD 4D Molecular Therapeutics, a prominent company in the field of genetic medicines with a focus on harnessing the full potential of geneti...

Find More

Johnson & Johnson
4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker

Gene therapy company 4D Molecular Therapeutics raises USD 90 Million to collaborate with AstraZeneca and Roche for moving gene therapies into clinical testing 4D Molecular Therapeutics has upraised USD 90 million in venture capital funds for progressing its vector platform and treatments, which use adeno-associate...

Find More